Diabetes & Endocrinology – Page 5

Insulin Metabolism as a Primary Driver of Cardiac Autonomic Dysfunction in Heart Failure: Insights from the Myovasc Study

By MedXY 02/03/2026

The Myovasc study demonstrates that insulin resistance and secretion markers, rather than glucose levels alone, are independently associated with impaired cardiac vagal activity in heart failure patients, suggesting a metabolic-autonomic axis that requires targeted clinical attention.

Diabetes & Endocrinology news

Precision Immunotherapy in Type 1 Diabetes: Baseline Beta-Cell Function as a Predictive Biomarker for Abatacept Efficacy

By MedXY 02/03/2026

A post-hoc analysis reveals that Abatacept significantly delays progression to Stage 2 or 3 Type 1 Diabetes specifically in individuals with higher baseline insulin secretion, marking a breakthrough in precision immunotherapy for early-stage disease.

Diabetes & Endocrinology news

Behavioral Diet Therapy Achieves Superior Postprandial Glycemic Control Over Gastric Bypass Despite Equivalent Weight Loss

By MedXY 02/03/2026

A dual-tracer study reveals that behavioral diet therapy provides greater postprandial glycemic improvement than Roux-en-Y gastric bypass after 20% weight loss in people with type 2 diabetes, driven by enhanced insulin-mediated glucose disposal unique to the dietary intervention.

Diabetes & Endocrinology news Ophthalmology

Evening Chronotype Linked to Progression of Diabetic Retinopathy and Poor Metabolic Control

By MedXY 02/03/2026

Recent longitudinal and cross-sectional data reveal that patients with an evening chronotype face significantly higher risks of diabetic retinopathy and metabolic dysregulation, independent of traditional glycemic markers like HbA1c.

Diabetes & Endocrinology Nephrology news

Precision Medicine Outperforms Standard Albuminuria Thresholds for SGLT2 Inhibitor Selection in Type 2 Diabetes

By MedXY 02/03/2026

A new precision medicine model identifies high-benefit patients for SGLT2 inhibitor treatment even when albumin levels appear normal, potentially preventing 10% more kidney failure events than current guidelines that rely solely on albuminuria thresholds.

Diabetes & Endocrinology Nephrology news

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY 02/03/2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various stages of renal impairment.

Cardiology Diabetes & Endocrinology news

Type 1 Diabetes Confers Double the Risk of Coronary Stent Failure Compared to Non-Diabetics: A SWEDEHEART Analysis

By MedXY 02/02/2026

A nationwide SWEDEHEART study reveals that while second-generation drug-eluting stents have improved outcomes, patients with Type 1 and Type 2 diabetes remain at significantly higher risk for stent failure, with Type 1 patients facing a more than twofold increased risk.

Cardiology Diabetes & Endocrinology news

Beyond Weight Loss: CagriSema Emerges as a Potent Antihypertensive in Obesity Management

By MedXY 02/02/2026

The REDEFINE 1 trial demonstrates that CagriSema, a semaglutide/cagrilintide combination, significantly reduces blood pressure in adults with overweight or obesity, even among those with resistant hypertension, while facilitating the reduction of concomitant antihypertensive medications.

Diabetes & Endocrinology Internal Medicine news

Substituting Water for Artificially Sweetened Beverages Fails to Improve Glycemic Control in Type 2 Diabetes: Results from the SODAS Trial

By MedXY 02/02/2026

The Study of Drinks with Artificial Sweeteners (SODAS) randomized trial reveals that replacing habitual artificially sweetened beverages with water does not improve HbA1c levels in patients with type 2 diabetes, with the water group surprisingly showing higher HbA1c levels than the beverage group.

Cardiology Diabetes & Endocrinology Nephrology news

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

By MedXY 02/02/2026

The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite kidney endpoint in a population with preserved baseline renal function.

Diabetes & Endocrinology Internal Medicine news

Beyond the Needle: GRADE Trial Debunks Myths on Insulin Distress and Confirms Adherence as the Glycemic Key

By MedXY 02/02/2026

A comprehensive analysis of the GRADE trial substudies reveals that adding basal insulin does not increase emotional distress in early T2DM and highlights the critical, predictive link between medication adherence and long-term glycemic success across different drug classes.

Diabetes & Endocrinology news Nursing & care

Nurse-Led Education Program Effectively Reduces Treatment Delay in Patients with Diabetic High-Risk Foot: A Randomized Controlled Trial

By MedXY 02/02/2026

This randomized controlled trial demonstrates that a structured nurse-led education intervention significantly improves foot care knowledge and self-efficacy while reducing both the intention and actual behavior of delaying treatment in patients with diabetic high-risk foot.

Diabetes & Endocrinology news Ophthalmology

Quantitative Retinal Leakage on Ultra-Widefield Imaging: A New Biomarker for Predicting Diabetic Retinopathy Progression

By MedXY 01/30/2026

A post hoc analysis of the DRCR Retina Network Protocol AA reveals that automated quantitative leakage index on ultra-widefield fluorescein angiography independently predicts the 4-year risk of DRSS worsening and vision-threatening complications in patients with nonproliferative diabetic retinopathy.

Diabetes & Endocrinology news Psychiatry

Mind the Gap: Patients with Mental Disorders Face Significant Disparities in Diabetes Monitoring and Modern Therapies

By MedXY 01/30/2026

A massive systematic review of 5.5 million patients reveals that those with mental disorders receive significantly lower quality diabetes care, including less frequent monitoring and a 74% lower likelihood of being prescribed GLP-1 receptor agonists compared to those without psychiatric conditions.

Diabetes & Endocrinology news Pediatrics

Delayed Puberty in Male Adolescents: A Novel Risk Factor for Early-Onset Type 2 Diabetes

By MedXY 01/30/2026

A nationwide cohort study of nearly 1 million Israeli males demonstrates that delayed puberty is independently associated with an increased risk of type 2 diabetes in early adulthood, suggesting it is a marker for long-term metabolic dysfunction.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation

By MedXY 01/26/2026

A nationwide Danish study suggests SGLT2 inhibitors offer superior protection against chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists in patients with type 2 diabetes, particularly for primary prevention.

Cardiology Diabetes & Endocrinology news

Beyond the LDL Receptor: Why ANGPTL3 Inhibition Is the New Gold Standard for Homozygous Familial Hypercholesterolemia

By MedXY 01/25/2026

Clinical trials and meta-analyses demonstrate that ANGPTL3 inhibitors, including SHR-1918 and zodasiran, provide superior LDL-C reduction compared to PCSK9 inhibitors in HoFH, particularly in patients with null-receptor genotypes where traditional therapies often fail.

Diabetes & Endocrinology Infectious Diseases news Public Health

High-Dose Influenza Vaccine Offers Superior Protection Against Hospitalization in Older Adults Regardless of Diabetes Status

By MedXY 01/25/2026

A secondary analysis of the DANFLU-2 trial demonstrates that high-dose influenza vaccines significantly reduce cardiorespiratory and influenza-related hospitalizations in adults aged 65 and older, with consistent benefits observed in patients with diabetes, particularly those with a disease duration exceeding five years.

Diabetes & Endocrinology Gastroenterology news

Berberine Improves Lipid Profiles and Inflammation but Fails to Reduce Visceral and Liver Fat in MASLD

By MedXY 01/24/2026

The BRAVO randomized clinical trial demonstrates that while 1 g/d of berberine significantly lowers LDL-C and hs-CRP in individuals with obesity and MASLD, it does not impact visceral adipose tissue area or liver fat content over a six-month period.

Diabetes & Endocrinology news Psychiatry

Smart Speakers for Diabetes: Bridging the Gap Between Mental Wellbeing and Glycemic Control in Older Adults

By MedXY 01/24/2026

The IVAM-ED trial demonstrates that interactive virtual assistants significantly reduce mental distress and improve HbA1c levels in older adults with type 2 diabetes, highlighting a scalable solution for geriatric chronic disease management.